Bio-Technopark
In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On a base area of 55,000 m2, the park now hosts 55 companies and many academic institutions representing a healthy mix of young start-ups and global companies as well as university clinics, institutes, and research groups.
Leasing
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with communal infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
Services
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
News
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals
Schlieren (Zurich), Switzerland, 15 July, 2021 – Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: XOMA) under which XOMA has purchased a proportion of the potential future pre-commercial milestone...
LimmaTech Biologics announces the start of a Phase I/II trial of a novel Klebsiella vaccine candidate.
Schlieren (Zurich), 8 July 2021 - LimmaTech Biologics AG today announced the start of a Phase I/II clinical trial in Germany of a 4-valent candidate vaccine to help prevent Klebsiella infections. LimmaTech is developing the asset in collaboration with GSK. Klebsiella is a bacterium threatening humans in many different settings, including...